[{"from": "human", "value": "Provide a brief overview of this molecule. [C][C][C][=C][Branch1][#Branch2][C][=C][C][=Branch1][Ring2][=C][Ring1][=Branch1][O][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][C][=Branch1][Branch1][=N][N][Ring1][#Branch1][C][=N][C][=C][Branch1][Ring2][N][Ring1][Branch1][C][N][Branch2][Ring1][Branch2][C@@H1][Branch1][Ring2][C][Ring1][#Branch1][C][=Branch1][C][=O][N][C][C][Branch1][Ring2][C][Ring1][Ring2][N][Branch1][C][C][C][C][Branch1][C][C][C]"}, {"from": "gpt", "value": "The molecule is a lung-selective inhibitor of the Janus associated-kinases (JAKs), with potential immunomodulatory and anti-inflammatory activities. Upon administration via nebulized inhalation, nezulcitinib inhibits the activity of the JAKs, thereby disrupting cytokine-induced activation of JAK-STAT signaling pathways in the airways. This may inhibit the release of pro-inflammatory cytokines and chemokines, reducing inflammatory responses and preventing inflammation-induced damage. The Janus kinase family of non-receptor tyrosine kinases, which includes tyrosine-protein kinase JAK1 (Janus kinase 1; JAK1), tyrosine-protein kinase JAK2 (Janus kinase 2; JAK2), tyrosine-protein kinase JAK3 (Janus kinase 3; JAK3) and non-receptor tyrosine-protein kinase TYK2 (tyrosine kinase 2), plays a key role in cytokine signaling."}]